Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SUTRO BIOPHARMA, INC.

(STRO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Sutro Biopharma, Inc.
Sutro Biopharma, Inc. is a clinical stage drug discovery, development and manufacturing company. The Company is focused on using its integrated cell-free protein synthesis platform, XpressCF, to create a variety of protein therapeutics for cancer and autoimmune disorders. It focuses to design therapeutics using potent modalities, including cytokine-based immuno-oncology (I/O) therapeutics, antibody-drug conjugates (ADCs) and bispecific antibodies that are directed primarily against clinically validated targets. Its product candidate includes STRO-001 and STRO-002. STRO-001 is an ADC directed against the cancer target CD74, for patients with multiple myeloma and non-Hodgkin lymphoma (NHL). STRO-002 is an ADC directed against folate receptor-alpha (FolRa), for patients with ovarian and endometrial cancers. STRO-001 and STRO-002 are designed and optimized for therapeutic index by placing linker-warheads at specific locations within the antibody using its XpressCF Platform.

Number of employees : 191 people.
Sales per Business
20192020Delta
Biopharmaceutical Products42.74100%42.72100% -0.03%
USD in Million
Sales per region
20192020Delta
United States42.74100%42.72100% -0.03%
USD in Million
Managers
Name Title Age Since
William J. Newell President, Chief Executive Officer & Director 62 -
Edward C. Albini Chief Financial Officer & Secretary 62 2013
Henry Heinsohn Vice President-Technology & Innovation - -
Trevor Hallam, Dr. Chief Scientific Officer & President-Research 61 2021
Arturo Molina, Dr. Chief Medical Officer 61 2016
Shabbir T. Anik, Dr. Chief Technical Operations Officer 67 2016
Craig Berman Vice President-Clinical Development - 2020
Nicki Vasquez, Dr. Senior VP-Operations & Alliance Management - -
John Gordon Freund, Dr. Independent Director 66 2014
Joseph M. Lobacki Independent Director 61 2017
Members of the board
Name Title Age Since
Connie Matsui Chairman 66 2019
William J. Newell President, Chief Executive Officer & Director 62 -
Daniel H. Petree Director 64 2009
John Gordon Freund, Dr. Independent Director 66 2014
Joseph M. Lobacki Independent Director 61 2017
Michael Dybbs, Dr. Independent Director 45 2018
Shalini Sharp Independent Director 43 2018
James P. Panek Director 66 2020
Jon Marc Wigginton, Dr. Director 58 2020
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 46,112,952 41,182,470 89.3% 0 0.0% 89.3%
Shareholders
NameEquities%
Merck & Co., Inc. 2,723,509 5.91%
Franklin Advisers, Inc. 2,627,066 5.70%
SSgA Funds Management, Inc. 2,514,164 5.45%
Eventide Asset Management LLC 2,370,975 5.14%
RA Capital Management LP 2,118,212 4.59%
First Light Asset Management LLC 2,058,447 4.46%
The Vanguard Group, Inc. 1,968,724 4.27%
SV Health Investors LLC 1,824,542 3.96%
Bristol-Myers Squibb Company 1,726,197 3.74%
Baillie Gifford & Co. 1,695,654 3.68%
Company contact information
Sutro Biopharma, Inc.
310 Utah Avenue
Suite 150
South San Francisco, CA 94080

Phone : +1.650.392.8412
Fax : +1.650.872.8924
Web : http://www.sutrobio.com
Sector Bio Therapeutic Drugs
1st jan.Capi. (M$)
SUTRO BIOPHARMA, INC.-21.42%899
GILEAD SCIENCES, INC.18.47%85 134
WUXI APPTEC CO., LTD.32.49%71 226
REGENERON PHARMACEUTICALS21.37%57 013
BIONTECH SE245.88%55 555
VERTEX PHARMACEUTICALS-15.16%50 308
BEIGENE, LTD.22.66%33 627
GENMAB A/S15.31%27 394
ARGENX SE10.70%16 311
HUALAN BIOLOGICAL ENGINEERING INC.-13.68%10 439
NEUROCRINE BIOSCIENCES, INC.2.79%9 482
ARROWHEAD PHARMACEUTICALS, INC.-10.90%9 401
DENALI THERAPEUTICS INC.-23.71%9 051
MIRATI THERAPEUTICS, INC.-28.46%8 451
FATE THERAPEUTICS, INC.-5.21%7 951
REMEGEN CO., LTD.-6.37%7 820
ACCELERON PHARMA INC.-4.01%7 722
ASCENDIS PHARMA A/S-30.65%7 555
EXELIXIS, INC.-16.64%7 340
GW PHARMACEUTICALS PLC89.72%6 907
AKESO, INC.26.84%6 690